Glaukos Corp (GKOS) - Net Assets

Latest as of March 2026: $670.93 Million USD

Based on the latest financial reports, Glaukos Corp (GKOS) has net assets worth $670.93 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($893.33 Million) and total liabilities ($222.40 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check tangible net worth ratio of Glaukos Corp to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric Value
Current Net Assets $670.93 Million
% of Total Assets 75.1%
Annual Growth Rate N/A
5-Year Change 11.75%
10-Year Change 459.51%
Growth Volatility 86.78

Glaukos Corp - Net Assets Trend (2012–2025)

This chart illustrates how Glaukos Corp's net assets have evolved over time, based on quarterly financial data. See Glaukos Corp defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Glaukos Corp (2012–2025)

The table below shows the annual net assets of Glaukos Corp from 2012 to 2025. For live valuation and market cap data, see GKOS market cap.

Year Net Assets Change
2025-12-31 $656.15 Million -14.44%
2024-12-31 $766.93 Million +66.09%
2023-12-31 $461.77 Million -12.88%
2022-12-31 $530.00 Million -9.73%
2021-12-31 $587.15 Million -12.03%
2020-12-31 $667.45 Million -0.86%
2019-12-31 $673.27 Million +287.25%
2018-12-31 $173.86 Million +25.80%
2017-12-31 $138.20 Million +17.85%
2016-12-31 $117.27 Million +23.20%
2015-12-31 $95.19 Million +159.16%
2014-12-31 $-160.90 Million -7.96%
2013-12-31 $-149.04 Million -1564.72%
2012-12-31 $-8.95 Million --

Equity Component Analysis

This analysis shows how different components contribute to Glaukos Corp's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 79852300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2025)

Component Amount Percentage
Common Stock $58.00K 0.01%
Other Comprehensive Income $3.30 Million 0.50%
Other Components $1.59 Billion 241.70%
Total Equity $656.15 Million 100.00%

Glaukos Corp Competitors by Market Cap

The table below lists competitors of Glaukos Corp ranked by their market capitalization.

Company Market Cap
Corporacion Acciona Energias Renovables SA
MC:ANE
 $7.68 Billion
SHIMANO INC. UNSP.ADR/10
F:SHM1
 $7.68 Billion
MITSU.CH.GRP ADR/5
F:M3C0
 $7.69 Billion
eMemory Technology
TWO:3529
 $7.69 Billion
Pandora A/S
CO:PNDORA
 $7.67 Billion
Houlihan Lokey Inc
NYSE:HLI
 $7.67 Billion
The Magnum Ice Cream Company N.V.
AS:MICC
 $7.67 Billion
ASM Pacific Technology Limited
F:AY7A
 $7.67 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Glaukos Corp's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2024 to 2025, total equity changed from 766,931,000 to 656,155,000, a change of -110,776,000 (-14.4%).
  • Net loss of 187,691,000 reduced equity.
  • Other comprehensive income increased equity by 688,000.
  • Other factors increased equity by 76,227,000.

Equity Change Factors (2024 to 2025)

Factor Impact Contribution
Net Income $-187.69 Million -28.6%
Other Comprehensive Income $688.00K +0.1%
Other Changes $76.23 Million +11.62%
Total Change $- -14.44%

Book Value vs Market Value Analysis

This analysis compares Glaukos Corp's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 11.39x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2012-12-31 $-1.45 $130.68 x
2013-12-31 $-5.68 $130.68 x
2014-12-31 $-6.08 $130.68 x
2015-12-31 $5.45 $130.68 x
2016-12-31 $3.22 $130.68 x
2017-12-31 $4.02 $130.68 x
2018-12-31 $4.92 $130.68 x
2019-12-31 $16.36 $130.68 x
2020-12-31 $15.00 $130.68 x
2021-12-31 $12.65 $130.68 x
2022-12-31 $11.17 $130.68 x
2023-12-31 $9.53 $130.68 x
2024-12-31 $14.54 $130.68 x
2025-12-31 $11.47 $130.68 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Glaukos Corp utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): -28.60%
  • The company may be facing challenges in efficiently utilizing shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: -36.99%
  • • Asset Turnover: 0.57x
  • • Equity Multiplier: 1.36x
  • Recent ROE (-28.60%) is below the historical average (-11.61%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2012 0.00% -795.84% 0.47x 0.00x $-19.04 Million
2013 0.00% -60.34% 0.68x 0.00x $1.49 Million
2014 0.00% -26.60% 1.75x 0.00x $3.00 Million
2015 -39.12% -51.94% 0.61x 1.23x $-46.76 Million
2016 3.86% 3.95% 0.85x 1.15x $-7.21 Million
2017 -0.07% -0.06% 0.96x 1.20x $-13.91 Million
2018 -7.45% -7.14% 0.88x 1.19x $-30.34 Million
2019 2.29% 6.51% 0.29x 1.22x $-51.90 Million
2020 -18.03% -53.50% 0.22x 1.51x $-187.09 Million
2021 -8.45% -16.87% 0.26x 1.92x $-108.31 Million
2022 -18.72% -35.07% 0.26x 2.03x $-152.20 Million
2023 -29.16% -42.79% 0.33x 2.04x $-180.84 Million
2024 -19.09% -38.17% 0.39x 1.27x $-223.07 Million
2025 -28.60% -36.99% 0.57x 1.36x $-253.31 Million

Industry Comparison

This section compares Glaukos Corp's net assets metrics with peer companies in the Medical Devices industry.

Industry Context

  • Industry: Medical Devices
  • Average net assets among peers: $339,406,921
  • Average return on equity (ROE) among peers: -53.68%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Glaukos Corp (GKOS) $670.93 Million 0.00% 0.33x $7.68 Billion
Abbott Laboratories (ABT) $2.09 Billion 30.22% 1.09x $153.73 Billion
Adagio Medical Holdings, Inc Common Stock (ADGM) $-95.88 Million 0.00% 0.00x $15.10 Million
Aethlon Medical Inc (AEMD) $-9.30 Million 0.00% 0.00x $2.49 Million
Acutus Medical Inc (AFIB) $-225.81 Million 0.00% 0.00x $903.35K
Adapthealth Corp (AHCO) $1.58 Billion 5.73% 1.84x $1.31 Billion
20/20 Biolabs, Inc. Common Stock (AIDX) $456.18K -277.12% 2.12x $6.80 Million
Allurion Technologies, Inc. (ALUR) $-34.28 Million 0.00% 0.00x $13.77 Million
Autonomix Medical, Inc. Common Stock (AMIX) $644.00K -309.01% 0.34x $4.16 Million
Artivion Inc (AORT) $80.23 Million 5.55% 0.17x $1.03 Billion
Apyx Medical Inc (APYX) $6.39 Million 7.83% 0.24x $172.10 Million

About Glaukos Corp

NYSE:GKOS USA Medical Devices
Market Cap
$7.68 Billion
Market Cap Rank
#2738 Global
#971 in USA
Share Price
$130.68
Change (1 day)
+2.57%
52-Week Range
$74.67 - $144.01
All Time High
$161.22
Categories
Companies in USA Medical Devices
About

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for a… Read more